Abstract

This third article in the series on antidepressants reviews the monoamine-oxidase inhibitors (MAOIs). A chance discovery by chest clinicians led to the development of this class of antidepressant medications. Although MAOIs are not the first choice in modern-day drug therapy due to significant side-effects and drug interactions, they have played an important role in the development of the pharmaceutical management of depression. Focusing on moclobemide for clarity, this article discusses the pharmacokinetics and pharmacodynamics of this class of drugs, before discussing precautions and prescribing in special populations. A summary of MAOIs currently in use and their alternative therapeutic indications is also presented.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.